# OnCo record elraglusib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/elraglusib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "elraglusib" ;
  schema:name "Elraglusib"@en ;
  schema:alternateName "9-ING-41"@en ;
  schema:description "Elraglusib blocks a kinase that helps pancreatic cancer resist chemotherapy; in a randomised phase 2 it lengthened survival when added to gemcitabine and nab-paclitaxel, and a phase 3 is planned."@en ;
  schema:url <https://onco.cc/drugs/elraglusib/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03678883>, <https://www.actuatetherapeutics.com>, <https://doi.org/10.1038/s41591-026-04327-4>, <https://doi.org/10.1016/j.esmoop.2025.105122> ;
  onco:status "phase-2" ;
  onco:modality "Small-molecule GSK-3 beta inhibitor" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:companies <https://onco.cc/companies/actuate-therapeutics/> ;
  onco:trials <https://onco.cc/trials/actuate-1801/> .